Literature DB >> 15215097

Patterns of amphotericin B killing kinetics against seven Candida species.

Emilia Cantón1, Javier Pemán, Miguel Gobernado, Angel Viudes, Ana Espinel-Ingroff.   

Abstract

In a previous study tolerance to amphotericin B (AMB) was found among Candida parapsilosis and C. dubliniensis strains by seeding the whole volumes of wells used for MIC determinations, and minimum fungicidal concentrations (MFC) for non-C. albicans Candida strains were demonstrated to be above the levels safely achievable in serum. As an extension of that study, we performed time-kill assays with 26 blood culture isolates (6 C. albicans, 5 C. parapsilosis, 5 C. krusei, 4 C. glabrata, 3 C. lusitaniae, and 3 C. tropicalis isolates), 3 oropharyngeal C. dubliniensis isolates, 3 AMB-susceptible isolates (ATCC 90028, ATCC 22019, ATCC 6254), and 6 AMB-resistant isolates (ATCC 200955, ATCC 200956, ATCC 200950, ATCC 200951, ATCC 200952, ATCC 200953) using RPMI 1640 medium and 0.12 to 32 microg of AMB per ml and determined the numbers of CFU per milliliter at 0, 2, 4, 8, 12, 24, and 48 h. MFCs and time-kill patterns were species specific (MFCs, < or =1 microg/ml for all C. dubliniensis and C. albicans isolates except AMB-resistant strain ATCC 200955; MFCs, 2 to >16 microg/ml for the other isolates). The times required to reach the fungicidal endpoint (99.9% killing) at four times the MIC were 2 h for C. albicans and C. dubliniensis, 16 h for C. glabrata, 24 h for C. parapsilosis and C. lusitaniae, and > or =40 h for C. tropicalis and C. krusei. The killing rate increased as the AMB concentration was increased up to 2 microg/ml. The highest killing rates were achieved for C. albicans, C. dubliniensis, and C. lusitaniae, while viable C. tropicalis, C. krusei, and C. parapsilosis cells were present after 48 h (MICs, < or =2 microg/ml) when AMB was used at 2 microg/ml. Time-kill curves and MFCs can detect viable cells after 48 h when AMB is used at > or =2 microg/ml. The failure of AMB treatment could be due to its poor killing activity against some species at the concentrations reached in patients' serum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215097      PMCID: PMC434204          DOI: 10.1128/AAC.48.7.2477-2482.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Overview of the lipid formulations of amphotericin B.

Authors:  Bertrand Dupont
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

2.  Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

Authors:  M H Nguyen; C J Clancy; V L Yu; Y C Yu; A J Morris; D R Snydman; D A Sutton; M G Rinaldi
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Authors:  M A Pfaller; D J Diekema; R N Jones; S A Messer; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.

Authors:  M A Pfaller; S A Messer; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1994-11       Impact factor: 2.803

7.  Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function.

Authors:  D J Drutz; R I Lehrer
Journal:  Am J Med Sci       Date:  1978 Jul-Aug       Impact factor: 2.378

8.  Development of resistance to amphotericin B in Candida lusitaniae infecting a human.

Authors:  D Pappagianis; M S Collins; R Hector; J Remington
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  Amphotericin B: time for a new "gold standard".

Authors:  Luis Ostrosky-Zeichner; Kieren A Marr; John H Rex; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2003-07-22       Impact factor: 9.079

10.  Amphotericin B-resistant yeast infection in severely immunocompromised patients.

Authors:  W G Powderly; G S Kobayashi; G P Herzig; G Medoff
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

View more
  36 in total

1.  Comparison of antifungal activities of gentian violet and povidone-iodine against clinical isolates of Candida species and other yeasts: a framework to establish topical disinfectant activities.

Authors:  Shigemi Kondo; Yoko Tabe; Toshihiko Yamada; Shigeki Misawa; Toyoko Oguri; Akimichi Ohsaka; Takashi Miida
Journal:  Mycopathologia       Date:  2011-08-12       Impact factor: 2.574

2.  Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study.

Authors:  L Majoros; I Szegedi; G Kardos; C Erdész; J Kónya; C Kiss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

Review 4.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Cholic Acid-Peptide Conjugates as Potent Antimicrobials against Interkingdom Polymicrobial Biofilms.

Authors:  Siddhi Gupta; Jyoti Thakur; Sanjay Pal; Ragini Gupta; Deepakkumar Mishra; Sandeep Kumar; Kavita Yadav; Amandeep Saini; Prabhu S Yavvari; Madhukar Vedantham; Archana Singh; Aasheesh Srivastava; Rajendra Prasad; Avinash Bajaj
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

6.  Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Authors:  Emilia Cantón; Javier Pemán; Macrina Sastre; Mónica Romero; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

7.  Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Serena Tomassetti; Daniela Arzeni; Daniele Giannini; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Activity of potent and selective host defense peptide mimetics in mouse models of oral candidiasis.

Authors:  Lisa K Ryan; Katie B Freeman; Jorge A Masso-Silva; Klaudia Falkovsky; Ashwag Aloyouny; Kenneth Markowitz; Amy G Hise; Mahnaz Fatahzadeh; Richard W Scott; Gill Diamond
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 9.  Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.

Authors:  Pedro Póvoa; João Gonçalves-Pereira
Journal:  Crit Care       Date:  2011-01-31       Impact factor: 9.097

10.  In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

Authors:  Emilia Cantón; Javier Pemán; Amparo Valentín; Ana Espinel-Ingroff; Miguel Gobernado
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.